<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509961</url>
  </required_header>
  <id_info>
    <org_study_id>PBMTC ONC1701</org_study_id>
    <nct_id>NCT03509961</nct_id>
  </id_info>
  <brief_title>The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL</brief_title>
  <official_title>A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL&#xD;
      patients with low risk of relapse as defined by absence of NGS-MRD (next generation&#xD;
      sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT).&#xD;
      Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a&#xD;
      test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be&#xD;
      eligible to receive a non-TBI conditioning regimen as part of the treatment cohort of the&#xD;
      study. Subjects who are pre-HCT NGS-MRD positive will be treated as per treating center&#xD;
      standard and will be followed in an observational cohort (HCT center standard of care).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase II pilot trial will estimate survival after a non-TBI based conditioning regimen in&#xD;
      patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic&#xD;
      hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual&#xD;
      disease (MRD) negative.&#xD;
&#xD;
      The relationship of NGS-MRD status to survival in children, adolescents, and young adults&#xD;
      with B-ALL undergoing any approach to allogeneic HCT will be explored in a larger cohort&#xD;
      (treatment [phase II] and observational arms of the study).&#xD;
&#xD;
      The primary objective is to estimate 2-year event free survival (EFS) in pre-HCT NGS-MRD&#xD;
      negative patients with B-ALL undergoing a non-TBI based conditioning regimen through a&#xD;
      multi-center prospective trial. The accrual period is 3 years.&#xD;
&#xD;
      Patients that are NGS-MRD negative with B-ALL may be eligible for the Treatment Arm, which is&#xD;
      myeloablative non-TBI conditioning with busulfan, fludarabine, and thiotepa followed -matched&#xD;
      related, unrelated, and umbilical cord blood transplants. Patients that are NGS-MRD positive&#xD;
      will be followed on the observational arm for outcome.&#xD;
&#xD;
      Study sampling will include NGS-MRD bone marrow (BM) aspirate and peripheral blood (PB)&#xD;
      samples collected [same day when possible] pre-HCT (within 4 weeks), and post-HCT on days 42&#xD;
      ± 14, 100 ± 20, and 365 ± 60; PB samples only will also be collected day 180± 60 and 270± 60;&#xD;
      day +30, day +100, and 1-year post-HCT. NGS-MRD peripheral blood sample only at 6 months and&#xD;
      9 months post-HCT; (Blast specimen at time of diagnosis or relapse is required for NGS-MRD&#xD;
      testing).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two Year Event-free Survival</measure>
    <time_frame>Two years</time_frame>
    <description>The primary objective of this study is the two Year Event-free Survival for patients with high-risk or recurrent B-ALL who proceed to HCT and who are NGS-MRD negative when treated with a non-TBI preparative regimen.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Observational Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are enrolled to the observational arm to proceed with NGS-MRD testing pre-HCT. If NGS-MRD negative, eligible patients may be considered for the Treatment Arm to receive a myeloablative non-TBI conditioning regimen prior to HCT.&#xD;
If NGS-MRD positive, patients may continue in the observational arm and receive HCT under the direction of their transplant physician and followed on the study for outcome.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients enrolled to the observational arm that are NGS-MRD pre-HCT are considered for the Treatment Arm. Patients will receive a myeloablative non-TBI conditioning regimen prior to the transplant consisting on busulfan, fludarabine and thiotepa. Patients will be followed for outcome for up to 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>NGS-MRD</intervention_name>
    <description>Next generation sequencing minimal residual disease (NGS-MRD) is a test that has increased sensitivity over multichannel flow cytometry to better identify risk of key outcomes after HCT. Patients that have a pre-HCT negative NGS-MRD results may be eligible to proceed to the treatment arm of the study that uses a non-TBI conditioning regimen.</description>
    <arm_group_label>Observational Arm</arm_group_label>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myeloablative allogeneic HCT with a non-TBI conditioning regimen</intervention_name>
    <description>Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.&#xD;
day -7: Fludarabine and Busulfan day -6: Fludarabine and Busulfan day -5: Fludarabine and Busulfan day -4: Fludarabine and Busulfan day -3: Fludarabine day -2: Thiotepa day -1: Rest Day 0: Transplant</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for the Observational Arm:&#xD;
&#xD;
        Any patient with ALL who undergoes Myeloablative HCT including any of the following:&#xD;
&#xD;
          -  Patients who are pre-HCT NGS-MRD positive.&#xD;
&#xD;
          -  Patients &lt;1 year old who are pre-HCT NGS-MRD negative.&#xD;
&#xD;
          -  Patients who are pre-HCT NGS-MRD negative (CR1/CR2) who received inotuzumab ozogamicin&#xD;
             therapy before proceeding to HCT.&#xD;
&#xD;
          -  Patients who are pre-HCT NGS-MRD negative and will be receiving haploidentical HCT.&#xD;
&#xD;
          -  Patients who are pre-HCT NGS-MRD negative in CR2 with history of CNS relapse.&#xD;
&#xD;
          -  Patients who have received blinatumomab, but are &gt;CR2 prior to HCT.&#xD;
&#xD;
          -  Patients who have received CART-T cellular therapy, but are &gt;CR2 prior to HCT.&#xD;
&#xD;
          -  Patients with pre-HCT NGS-MRD negative in ≥ CR3.&#xD;
&#xD;
          -  Any T-ALL and MPAL patients undergoing first allogeneic HCT&#xD;
&#xD;
          -  Any patient who is pre-HCT NGS-MRD negative and eligible for participation in the&#xD;
             treatment arm but family does not consent for treatment arm or treating physician&#xD;
             believe it is in the patient best interest not to enroll on the treatment arm&#xD;
&#xD;
        Inclusion Criteria for the Treatment Arm:&#xD;
&#xD;
          -  Pre-HCT NGS-MRD negative&#xD;
&#xD;
          -  Age ≥ 1 year and ≤ 25 years&#xD;
&#xD;
          -  Disease status: B-ALL in first (CR1) or second remission (CR2)&#xD;
&#xD;
          -  No prior allogeneic hematopoietic stem cell transplant.&#xD;
&#xD;
          -  Patients in CR1 or CR2 after blinatumomab treatment.&#xD;
&#xD;
          -  Patients in CR1 or CR2 after CAR-T cellular therapy.&#xD;
&#xD;
          -  Karnofsky Index or Lansky Play-Performance Scale ≥ 60 % on pre-transplant evaluation.&#xD;
             Karnofsky scores must be used for patients &gt; 16 years of age and Lansky scores for&#xD;
             patients &lt; 16 years of age.&#xD;
&#xD;
          -  Able to give informed consent if &gt; 18 years, or with a legal guardian capable of&#xD;
             giving informed consent if &lt; 18 years.&#xD;
&#xD;
          -  Adequate organ function (within 4 weeks of initiation of preparative regimen), defined&#xD;
             as:&#xD;
&#xD;
          -  Pulmonary: FEV1, FVC, and corrected DLCO must all be ≥ 50% of predicted by pulmonary&#xD;
             function tests (PFTs). For children who are unable to perform for PFTs due to age, the&#xD;
             criteria are: no evidence of dyspnea at rest and no need for supplemental oxygen.&#xD;
&#xD;
          -  Renal: Creatinine clearance or radioisotope GFR ≥ 60 mL/min/1.73 m2 or a serum&#xD;
             creatinine based on age/gender.&#xD;
&#xD;
          -  Cardiac: Shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA) or&#xD;
             ejection fraction of ≥ 50% by echocardiogram or radionuclide scan (MUGA), choice of&#xD;
             test according to local standard of care.&#xD;
&#xD;
          -  Hepatic: SGOT (AST) or SGPT (ALT) &lt; 5 x upper limit of normal (ULN) for age.&#xD;
             Conjugated bilirubin &lt; 2.5 mg/dL, unless attributable to Gilbert's Syndrome.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CR2: exclude patients with history of CNS relapse (i.e. in CR2 with history of CNS&#xD;
             isolated or combined relapse; CNS 2 will also be considered as CNS 3 for this purpose)&#xD;
             from the treatment arm of study (can be enrolled on the observational arm).&#xD;
&#xD;
          -  Patients who have received inotuzumab treatment prior to allogeneic HCT are NOT&#xD;
             eligible for the study treatment arm. Inotuzumab treatment may increase the risk of&#xD;
             VOD/SOS for any allogeneic HCT recipient, but could potentiate the risk for with&#xD;
             busulfan-based myeloablation (study-directed non-TBI conditioning). All&#xD;
             inotuzumab-treated patients are eligible for the observational arm (HCT center&#xD;
             standard of care).&#xD;
&#xD;
          -  Patients receiving non-myeloablative conditioning are not allowed on the observational&#xD;
             arm (reduced toxicity conditioning with Flu/Mel/Thio is allowed on the observational&#xD;
             arm).&#xD;
&#xD;
          -  Pregnant or lactating females are ineligible as many of the medications used in this&#xD;
             protocol could be harmful to unborn children and infants.&#xD;
&#xD;
          -  Patients with HIV or uncontrolled fungal, bacterial or viral infections are excluded.&#xD;
             Patients with history of fungal disease during induction therapy may proceed if they&#xD;
             have a significant response to antifungal therapy with no evidence or minimal evidence&#xD;
             of non-progressive disease remaining by CT evaluation.&#xD;
&#xD;
          -  Patients with active CNS leukemia or any other active site of extramedullary disease&#xD;
             at the time of enrollment are not permitted.&#xD;
&#xD;
          -  T-ALL and MPAL patients are only allowed on the observational arm.&#xD;
&#xD;
          -  Patients with genetic disorders (generally marrow failure syndromes) prone to&#xD;
             secondary AML/ALL with known poor outcome are not eligible (Fanconi Anemia, Kostmann&#xD;
             Syndrome, Dyskeratosis Congenita, etc).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisham Abdel-Azim, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Troy Quigg, DO</last_name>
    <role>Study Chair</role>
    <affiliation>Methodist Hospital - Texas Transplant Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liz Gourdine</last_name>
    <phone>323-361-6652</phone>
    <email>EndRAD@chla.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's of Alabama/University of Alabama in Birmingham(UAB)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Beatty</last_name>
      <phone>205-638-9364</phone>
      <email>lbeatty@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Chewning, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desiree Tobin</last_name>
      <email>dtobin@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Dana Salzberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Tahoun, MBBS, MBA</last_name>
      <phone>626-218-4350</phone>
      <email>atahoun@coh.org</email>
    </contact>
    <investigator>
      <last_name>Anna Pawlowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aunsha Williamson</last_name>
      <phone>323-361-7551</phone>
      <email>awilliamson@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Hisham Abdel-Azim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Mattel Children's Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Vargas</last_name>
      <phone>310-825-6742</phone>
      <email>AndresVargas@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Ted Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Klein</last_name>
      <phone>510-597-7169</phone>
      <email>jklein@mail.cho.org</email>
    </contact>
    <investigator>
      <last_name>nahal Lalefar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Magruder</last_name>
      <phone>415-476-3834</phone>
      <email>Kevin.Magruder@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Christine Higham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marguerite Dyer</last_name>
      <phone>720-777-5230</phone>
      <email>marguerite.dyer@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Amy Keating, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Eford</last_name>
      <phone>203-737-6219</phone>
      <email>Linda.eford@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Niketa Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children - Nemours Deleware</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ande Wrightson</last_name>
      <phone>302-651-5584</phone>
      <email>Andrea.Wrightson@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Emi Caywood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beate Greer</last_name>
      <email>bgreer01@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Biljana Horn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido Elias</last_name>
      <phone>786-624-3513</phone>
      <email>Guido.Elias@Nicklaushealth.org</email>
    </contact>
    <investigator>
      <last_name>Jorge Galvez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Titus</last_name>
      <phone>727-767-3229</phone>
      <email>Ktitus2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Shrine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judson Russell</last_name>
      <email>Judson.Russell@choa.org</email>
    </contact>
    <investigator>
      <last_name>Muna Qayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children - Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Spiegel</last_name>
      <phone>317-948-0581</phone>
      <email>clorch@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Jodi Skiles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Floating Hospital for Children at Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Chisholm</last_name>
      <email>jchisholm1@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Jason Law, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Faber Cancer Institute/ Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea DeMarsh</last_name>
      <phone>617-632-3483</phone>
      <email>Andrea_Demarsh@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Margossian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Paulsen</last_name>
      <phone>616-391-5075</phone>
      <email>Laura.Paulsen@spectrumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ulrich Duffner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Walters</last_name>
      <phone>816-302-6894</phone>
      <email>kdwalters@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Ibrahim Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elana Smilow</last_name>
      <phone>551-996-5673</phone>
      <email>Elana.smilow@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Krajewski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Brucato</last_name>
      <phone>716-845-8968</phone>
      <email>Patti.Brucato@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Barbara Bambach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health - Levine Cancer Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Fukes</last_name>
      <phone>980-442-2310</phone>
      <email>Tracy.Fukes@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Huo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas M. D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry Melton</last_name>
      <phone>713-745-1473</phone>
      <email>sjmelton@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Kris Mahadeo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candace Taylor</last_name>
      <phone>210-575-7379</phone>
      <email>Candace.taylor@mhshealth.com</email>
    </contact>
    <investigator>
      <last_name>Troy Quigg, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>Hisham Abdel-Azim</investigator_full_name>
    <investigator_title>Attending Physician, Hematopoietic Stem Cell Transplantation Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

